Anderson et al. investigated 67 patients with R/R CLL receiving venetoclax in 3 early-phase trials and identified BCL2 G101V in 11 cases with all patients ultimately experiencing disease progression [11,20]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.